An Open-label, Multicenter Clinical Study on The Long-term Safety and Efficacy of Multiple Treatments With Recombinant Botulinum Toxin Type A (YY001) for Injection in Adult Upper Limb Spasticity (REHAB-2)
Latest Information Update: 23 Mar 2026
At a glance
- Drugs YY-001 (Primary)
- Indications Muscle spasticity
- Focus Adverse reactions; Registrational
- Acronyms REHAB-2
- Sponsors Chongqing Claruvis Pharmaceutical
Most Recent Events
- 23 Mar 2026 New trial record